Histogen Inc. (HSTO)

NASDAQ: HSTO · IEX Real-Time Price · USD
1.26
+0.06 (5.00%)
Mar 30, 2023, 10:25 AM EDT - Market open
5%
Market Cap 5.40M
Revenue (ttm) 3.77M
Net Income (ttm) -11.11M
Shares Out 4.27M
EPS (ttm) -3.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,262
Open 1.22
Previous Close 1.20
Day's Range 1.20 - 1.27
52-Week Range 0.76 - 9.40
Beta 0.99
Analysts Buy
Price Target 2.04 (+61.91%)
Earnings Date May 11, 2023

About HSTO

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, whi... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Stephen J. Mento Ph.D.
Employees 22
Stock Exchange NASDAQ
Ticker Symbol HSTO
Full Company Profile

Financial Performance

In 2022, Histogen's revenue was $3.77 million, an increase of 265.21% compared to the previous year's $1.03 million. Losses were -$11.11 million, -25.69% less than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for HSTO stock is "Buy." The 12-month stock price forecast is $2.04, which is an increase of 61.91% from the latest price.

Price Target
$2.04
(61.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is Histogen (HSTO) Stock Up 37% Today?

Histogen (NASDAQ: HSTO) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhibitors and Methods of Use Thereof.

1 week ago - InvestorPlace

Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use

The Newly Issued Patent is Expected to Provide Protection into 2040

1 week ago - GlobeNewsWire

Histogen Reports Year-End 2022 Results and Provides Business Update

Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory D...

2 weeks ago - GlobeNewsWire

Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments fo...

1 month ago - GlobeNewsWire

Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration

MCLEAN, Va.--(BUSINESS WIRE)--Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19.

2 months ago - Business Wire

Histogen (HSTO) Upgraded to Strong Buy: Here's What You Should Know

Histogen (HSTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Histogen Hires Alfred P. Spada Ph.D.

Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory D...

3 months ago - GlobeNewsWire

Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-...

4 months ago - GlobeNewsWire

Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

Closed $5M Financing in July

8 months ago - GlobeNewsWire

Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...

8 months ago - GlobeNewsWire

Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...

9 months ago - GlobeNewsWire

Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...

9 months ago - GlobeNewsWire

Why Is Histogen (HSTO) Stock Soaring 35% Today?

Histogen (HSTO) stock is rocketing higher on Tuesday despite a lack of news concerning the clinical-stage therapeutics company. The post Why Is Histogen (HSTO) Stock Soaring 35% Today?

9 months ago - InvestorPlace

Histogen Announces 1-for-20 Reverse Stock Split

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...

10 months ago - GlobeNewsWire

Histogen to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selectiv...

11 months ago - GlobeNewsWire

Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

Received $3.75 Million Payment from Allergan

11 months ago - GlobeNewsWire

CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D.

SAN DIEGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: PARACRINE ANNOUNCES APPOINTMENT OF BIOTECH VETERAN DAV...

11 months ago - Business Wire

Paracrine Announces Appointment of Biotech Veteran David Crean, Ph.D. to the Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, announced today the appointment of David Crean, ...

11 months ago - Business Wire

Histogen to Report First Quarter 2022 Financial Results and Provide Business Update

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase select...

11 months ago - GlobeNewsWire

Histogen Announces Closing of $4.75 Million Private Placement

SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natu...

1 year ago - GlobeNewsWire

Histogen Announces $4.75 Million Private Placement

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natu...

1 year ago - GlobeNewsWire

Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ong...

1 year ago - GlobeNewsWire

Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite th...

1 year ago - GlobeNewsWire

Histogen Announces Closing of $3.5 Million Private Placement

SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natur...

1 year ago - GlobeNewsWire

Histogen Announces $3.5 Million Private Placement

SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natur...

1 year ago - GlobeNewsWire